On the contrary, CLL patients with IGH/BCL2 have not shown association with complex karyotype or aggressive features that could trigger a poorer outcome of this subgroup of IGH-translocated patients (Figure 1) [88]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.